Skip to content

Application of fiberoptic bronchoscope assisted nasogastric feeding tube insertion in neuro-critically ill patients

Application of fiberoptic bronchoscope assisted nasogastric feeding tube insertion in neuro-critically ill patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064011
Enrollment
Unknown
Registered
2022-09-23
Start date
2022-09-23
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuro-critical illness

Interventions

experimental group:nasogastric tube insertion under the guidance of fiberoptic bronchoscope
control group:conventional nasogastric tube insertion

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Critically ill neurological patients aged >= 18 years; 2. According to the needs of the clinical condition, a deputy senior doctor of neurology or rehabilitation department and above, and a nurse in charge and a nurse of above level have determined that bedside indwelling nasogastric tube operation is necessary; 3. The patient or legal representative signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Malnourished or obese children; 2. Cushing's syndrome, pituitary tumor, adrenal tumors such as endocrine system diseases; 3. Severe respiratory diseases (obstructive sleep apnea syndrome, acute respiratory tract infection, uncontrolled asthma, active massive hemoptysis, pulmonary hypertension, etc.); 4. Any congenital heart disease, acute heart failure, atrioventricular block, or severe arrhythmia; 5. Infectious heart disease such as myocarditis or endocarditis; Sepsis; Pneumonia; 6. Paients suffering from mental system diseases (autism, ADHD, schizophrenia), abnormal brain development and cognitive dysfunction; 7. Anemia or thrombocytopenia: HbULN+3s and/or APTT>ULN+10s); 9. Abnormal liver function: AST and/or ALT>=2.5xULN, TBIL>=1.5xULN; 10. Abnormal renal function: urea or urea nitrogen >=1.5xULN, blood creatinine greater than the upper limit of normal value; 11. Patients whose blood glucose was not satisfactorily controlled (random blood glucose >=11.1mmol/L during the screening period); 12. Allergic or contraindicated to benzodiazepines, opiates, etomidate, propofol, ketamine and other drugs and their components; 13. Patients judged to have difficulty managing the respiratory tract (modified Markov score level ?); 14. Participated in any clinical drug trial as a subject and used the test drug within the last 3 months; 15. Take monoamine oxidase inhibitors for 2 weeks; 16. Taking sedative drugs, antiemetic drugs, motion sickness drugs and anti-pruritus drugs within 48 hours before surgery; 17. Other factors that might interfere with the results of the experiment.

Design outcomes

Primary

MeasureTime frame
Separation Anxiety Score from Parents(PSAS);Mask Induction Acceptance Score;Modified Ramsay Sedation Score;

Secondary

MeasureTime frame
Children's behavior scores at the time of drug administration;Children's modified sedation Ramsay score every 5 minutes after taking the drug;Whether remedial sedation has occurred;Parent satisfaction;

Countries

China

Contacts

Public ContactLadi Luo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

luola0621@163.com+86 18927547616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026